Supralselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma

Lejla Mutapcic Vajzovic1
Timothy G Murray1
Mohammad A Aziz-Sultan2
Amy C Schefler1
Stacey Quintero Wolfe2
Ditte Hess1
Cristina E Fernandes3
Sander R Dubovy1,4

1Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA; 2Department of Neurological Surgery, University of Miami/Jackson Memorial Hospital, Miami, FL, USA; 3Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA; 4Florida Lions Oculopathology Laboratory, Miami, FL, USA

Purpose: The purpose of this study is to report the complication profile and safety evaluation of supralselective intra-arterial melphalan chemotherapy in children undergoing treatment with advanced retinoblastoma.

Methods: Twelve eyes of 10 children with advanced retinoblastoma (Reese-Ellsworth Group Vb or International Classification Group D) were treated with supralselective intra-ophthalmic artery infusion of melphalan. Eleven eyes of nine children had previously failed traditional management with systemic chemotherapy and laser ablation and underwent intra-ophthalmic artery infusion of melphalan as an alternative to enucleation. Serial ophthalmic examinations, retinal photography, and ultrasonographic imaging were used to evaluate treatment regime.

Results: Ophthalmic artery cannulation was successfully performed in 12 eyes of 10 patients (total 16 times). Striking regression of tumor, subretinal and vitreous seeds were seen early in each case. No severe systemic side effects occurred. Grade III neutropenia was seen in one patient. No transfusions were required. Three patients developed a vitreous hemorrhage obscuring tumor visualization. One patient developed periocular edema associated with inferior rectus muscle inflammation per orbital MRI. This same patient had scattered intraretinal hemorrhages and peripapillary cotton wool spots consistent with a Purtscher’s-like retinopathy that resolved spontaneously. At the 6-month follow-up examination, nine eyes had no evidence of tumor progression, whereas three eyes were enucleated for tumor progression. In each enucleated case, viable tumor was identified on histopathologic examination.

Conclusions: Ophthalmic intra-arterial infusion with melphalan is an excellent globe-conserving treatment option in advanced retinoblastoma cases with minimal systemic side effects. Local toxicities include microemboli to the retina and choroid (1/12, 8%), vitreous hemorrhage (3/12, 25%), and myositis (1/12, 8%). Enucleation remained a definitive treatment for tumor progression in 3 of 12 eyes in this small case series with limited follow-up. Further studies are necessary to establish the role of supralselective intra-arterial melphalan chemotherapy for children with retinoblastoma.

Keywords: retinoblastoma, intra-arterial chemotherapy, melphalan

Introduction

Retinoblastoma is the most common intraocular tumor in childhood, occurring in -1 in 15,000 live births, with 300 newly diagnosed children each year in the United States.1,2 Historically, treatment for children with advanced retinoblastoma involved enucleation and external beam radiation therapy that has significant complications including midfacial disfigurement and secondary primary malignancies.3,4 For over a decade, treatment has been focused on globe-preserving techniques including systemic chemotherapy and a combination of focal consolidative therapy including brachyther-
apy, laser photocoagulation, cryotherapy, or thermotherapy. Although this treatment approach has resulted in significant improvement in survival rates, up to 99% in the developed world, systemic chemotherapy frequently leads to serious toxic side effects including myelosuppression, infection, and the need for blood transfusion in up to 75% of cases.6-8 As a result, newer treatment approaches have involved localized delivery of chemotherapy to minimize systemic side effects of chemotherapy and have included periorcular injection of carboplatin and intra-ophthalmic artery infusion of the chemotherapeutic drug melphalan.9,10 However, recently concerns have been raised regarding periocular carboplatin with reports of severe localized side effects, such as extraocular motility changes, optic nerve toxicity, and periorbital fat necrosis with enophthalmia.10-12 Intra-arterial injection of melphalan in retinoblastoma patients has been reported by Yamane et al, Abramson et al, and our group.13-17 Herein, we summarize the treatment of 12 eyes of 10 children with advanced intraocular retinoblastoma (Reese-Ellsworth Group Vb or International Classification Group D, who would generally undergo enucleation) with intra-ophthalmic artery infusion of melphalan.

Materials and methods

Under general anesthesia, the femoral artery cannulation was performed with a sterile 21-gauge micropuncture. A heparin bolus (60 units/kg IV) was administered to anticoagulate the patient. Additional heparin boluses were given based on hourly measurement of activated clotting time (ACT) with a goal of ACT between 200 and 250 sec. Under fluoroscopic X-ray guidance, a 4-French (F) guide catheter was maneuvered over a wire through the aortic arch into the ipsilateral external and internal carotid arteries (ICA) through which digital subtracted angiography was performed to assess vascular supply to the orbit. A Marathon microcatheter (EV3, Irvine, CA, USA) was then advanced over a Mirage microguide wire (EV3, Irvine, CA, USA) and into the ostium of the ophthalmic artery where a selective ophthalmic artery angiography was performed. The desired dose of melphalan was diluted in 30 cc of normal saline and infused by pulse injection over 30 min. Ophthalmic artery and ipsilateral ICA angiography were repeated to rule out any inadvertent thromboembolic episodes. All patients tolerated the procedure.

Ophthalmic evaluations under anesthesia were performed approximately every 4 weeks after intra-arterial chemotherapy was completed and consisted of external and anterior segment examination for any evidence of iris neovascularization, hyphema, or hypopyon, indirect ophthalmoscopy with 360° of scleral depression, Ret Cam digital fundus photography (Massie Industries, Dublin, CA, USA) documenting all lesions, and B-scan ultrasonography (10 MHz). Between evaluations under anesthesia, the pediatric oncologist performed systemic evaluation including an interval history and complete blood counts.

Results

This report summarizes our initial experience with intra-ophthalmic artery infusion of the chemotherapeutic agent melphalan in 12 eyes of 10 children, all diagnosed with Reese-Ellsworth Group Vb or International Classification Group D retinoblastoma (unilateral 6, bilateral 4) (Table 1). Nine patients were previously treated with systemic chemotherapy in a combination with laser photocoagulation. Systemic chemotherapy included carboplatin, vincristine, etoposide, and/or cyclosporine for nine cycles except for one patient who received 11 cycles. At the subsequent exams and as tumor progression was noted, seven patients were treated with periocular injections of carboplatin and one patient in addition had external beam radiation. Only patient #10 received intra-arterial melphalan and laser photocoagulation as the primary treatment, while the other nine patients received intra-arterial melphalan and laser photocoagulation as salvage therapy in the setting of disease progression after systemic chemotherapy and focal therapy.

All attempts at supraselective intra-arterial drug delivery were successful. There were 16 separate infusions in 10 patients. Eight patients had unilateral and two patients had bilateral infusions. Four patients received repeat melphalan infusion at higher doses due to initial incomplete tumor response. The mean follow-up was 5.5 months and the median was 5.0 months. At the 5-month follow-up examination, nine eyes had no evidence of tumor progression. Three eyes required enucleation. The indications for enucleation were vitreous hemorrhage obscuring visualization of tumor, peripapillary tumor with concern for optic nerve invasion, and continued tumor progression. In each enucleated case, viable tumor was identified on histopathologic examination. These findings have been described elsewhere.13

Overall, 76.5% of tumors responded to therapy avoiding enucleation. Of the responders, 54% responded to single dose of melphalan. Representative cases before and after treatment are illustrated (Figures 1–3).

There were no severe systemic complications including fevers, infections, red blood cell or platelet transfusions, stroke or death. Grade III neutropenia was seen in one patient at 1 week. Scrotal hematoma at the femoral artery puncture site was noted in patient #9. Vitreous hemorrhage was
## Table 1
Data on the first 12 eyes of 10 patients with retinoblastoma treated with intra-arterial melphalan

<table>
<thead>
<tr>
<th>Pt no.</th>
<th>Age at Dx (years)</th>
<th>Laterality</th>
<th>R-E group</th>
<th>ICRB group</th>
<th>Previous tx</th>
<th>Age at first IAM (months)</th>
<th>Eye(s) tx</th>
<th>Dose (mg) with each Dx</th>
<th>F/U interval since IAM (months)</th>
<th>Complications after Dx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>U</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>34</td>
<td>OS</td>
<td>3.75</td>
<td>6</td>
<td>Yes; No</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>U</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>59</td>
<td>OS</td>
<td>5</td>
<td>5</td>
<td>Yes; No</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>B</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>21</td>
<td>OU</td>
<td>OD 5, 7.5; OS 3</td>
<td>5</td>
<td>No; No; Grade III neutropenia</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>B</td>
<td>OD II; OS Vb</td>
<td>Yes</td>
<td>25</td>
<td>OU</td>
<td>OD 2; OS 2, 7.5</td>
<td>6</td>
<td>No; Yes</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>B</td>
<td>OD II; OS Vb</td>
<td>Yes</td>
<td>17</td>
<td>OU</td>
<td>OS 3</td>
<td>6</td>
<td>No; Yes</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>B</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>33</td>
<td>OS</td>
<td>3</td>
<td>6</td>
<td>No; No; No; No; No; No; No; No</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>U</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>20</td>
<td>OD</td>
<td>3.75</td>
<td>5</td>
<td>No; No; No; No; No; No</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>U</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>46</td>
<td>OD</td>
<td>5</td>
<td>5</td>
<td>No; No</td>
</tr>
<tr>
<td>9</td>
<td>8</td>
<td>B</td>
<td>Vb</td>
<td>D</td>
<td>Yes</td>
<td>95</td>
<td>OS</td>
<td>5</td>
<td>6</td>
<td>No; No</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>U</td>
<td>Vb</td>
<td>D</td>
<td>No</td>
<td>83</td>
<td>OD</td>
<td>7.5</td>
<td>5</td>
<td>No; No; No; No; No; No; No</td>
</tr>
</tbody>
</table>

**Abbreviations:** B, bilateral retinoblastoma; Dx, diagnosis; F/U, follow-up; IAM, intra-ophthalmic artery infusion of melphalan; ICRB, international classification of retinoblastoma group; OD, right eye; OS, left eye; OU, both eyes; Pt, patient; R-E, Reese-Ellsworth; U, unilateral retinoblastoma; VH, vitreous hemorrhage.

Complications:
- Patient #10 developed periocular swelling, and an MRI of orbits showed inferior rectus muscle inflammation. Dilated funduscopic examination showed Purtscher’s-like retinopathy with peripapillary cotton wool spots and scattered intraretinal hemorrhages in the treated eye most likely due to an embolic event. These findings resolved spontaneously on close follow-up (Figure 3).

## Discussion
This report describes our experiences with supraselective intra-arterial melphalan infusion in patients with advanced retinoblastoma unresponsive to systemic chemotherapy and focal treatment.

Recently, local treatments including periocular administration of carboplatin and intravitreal melphalan have been suggested as alternative modalities to systemic chemotherapy, especially in eyes with advanced disease. In Japan, clinicians have been investigating intracranial melphalan infusion for the past 15 years. They have reported good outcomes after selective intra-arterial melphalan infusion. In the United States, Abramson et al. recently reported that patients with advanced intra-arterial melphalan have been successfully treated. These patients have had poor retinographic profiles at baseline, and these eyes also received external beam radiation therapy in 97.5% of 563 treatments. They have been successful in 97.5% of these patients, with no severe local or systemic side effects.

At our institution, we have treated 12 eyes of 10 patients with retinoblastoma with selective intra-arterial melphalan at varying doses. All patients had advanced retinoblastoma Reese-Ellsworth Group Vb or International Classification Group D, and all with multiagent chemoresistant retinoblastoma. None of these patients reported initial follow-up after intra-arterial melphalan infusion and was self-limiting in cases #4 and #5. Patient #10 developed periocular swelling and an MRI of melanoma infarction and was self-limiting in cases #4 and #5.

Patient #10 developed periocular swelling, and an MRI of melanoma infarction and was self-limiting in cases #4 and #5.
duction therapy combined with laser photocoagulation. In addition, one patient was treated with external beam radiation without success. In 11 eyes, the decision was made to proceed with intra-arterial melphalan combined with focal laser photocoagulation as a salvage treatment option before standard enucleation. At a 3–4 week follow-up interval after intra-arterial melphalan treatment, a marked response with regression of retinal tumor, subretinal/vitreous seeds was noted in all patients. One eye in our series was treated with intra-arterial melphalan as a primary treatment

Figure 1 Patient #8 diagnosed with unilateral advanced Reese-Ellsworth Group Vb or International Classification Group D retinoblastoma previously treated with systemic chemoreduction and focal consolidative treatment, then periocular carboplatin injections without tumor regression. As a salvage therapy, intra-arterial melphalan infusion at 5 mg was performed, which lead to tumor regression. A) At presentation. B) After systemic chemoreduction and focal laser photocoagulation. C) Five months after a single infusion of melphalan at 5-mg dose.

Figure 2 Patient #1 presented with Reese-Ellsworth Group Vb or International Classification Group D retinoblastoma initially treated with systemic multiagent chemoreduction (carboplatin, vincristine, etoposide, and cyclosporine) with focal laser photocoagulation and subsequently with six periocular carboplatin injections. Even with this aggressive treatment, the tumor continued to progress. The patient then underwent intra-arterial melphalan infusion as salvage therapy at the 3-mg dose and then at the 7.5-mg dose. Subsequently, the patient developed a vitreous hemorrhage obscuring tumor visualization. Echographic evaluation demonstrated tumor progression, and the patient underwent definitive therapy with enucleation. A) At presentation. B) Before first melphalan infusion (3-mg dose). C) Before second melphalan infusion (7.5 mg).
Complications related to intra-arterial chemotherapy in retinoblastoma

Previously had undergone extended chemoreduction, laser photocoagulation, and periocular carboplatin injections. On histopathologic examination of enucleated eyes, viable tumor was noted in all three cases.15

Although intra-arterial infusion of melphalan has shown promising results, we have noted several local side effects. These side effects included vitreous hemorrhage in three patients and Purtsher’s-like retinopathy secondary to an embolic event as well as inferior rectus inflammation in another patient. In two of three patients, vitreous hemorrhage was self-limited, and tumor regression was achieved. The third patient with vitreous hemorrhage underwent enucleation for tumor progression. The Purtsher’s-like retinopathy findings in the latter patient resolved spontaneously, and complete tumor regression was noted at last follow-up. No severe systemic complications were identified during posttreatment period including fever, nausea, vomiting, alopecia, bone marrow suppression, sepsis, or any other condition requiring hospitalization.

In our experience, intra-arterial infusion of melphalan has been successful in achieving effective tumor reduction in advanced retinoblastoma cases primarily as globe-salvage therapy after failure of systemic chemotherapy combined with focal therapy. This alternative globe-preserving treatment has dramatically decreased enucleation rate at our institution. It should be noted that this approach requires consolidation with focal therapy, such as laser, after completion of intra-arterial chemotherapy. Clinicians offering this treatment modality should be aware of short-term potential local adverse effects, such as vitreous hemorrhage and Purtsher’s-like retinopathy as well as lack of tumor response. Larger patient series are needed to establish the role of supraselective intra-arterial melphalan chemotherapy for children with retinoblastoma. Collaborative series among large institutions are currently in development with the Children’s Oncology Group and these series will greatly advance the rate at which we can learn more about this exciting therapy since retinoblastoma is a rare disease.

Disclosure

The authors report no conflicts of interest in this work.

References


